New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): Vitamin D analogues and calcium-mimetics;Nuevas estrategias terapéuticas para el hiperparatiroidismo secundario en diálisis (II): Análogos de la vitamina D y calcimiméticos

Nefrologia

Volumn 25, Issue SUPPL.2, 2005, Pages 109-116

  Bover, J ^a   Ballarin J ^a   Andres E ^a   Ortiz Herbener, F ^a   Barcelo P ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acidosis; Analogs; Calcimimetics; Chronic renal disease; Cinacalcet; Dialysis; Paricalcitol; Phosphorus; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CALCIUM; CINACALCET; DRUG DERIVATIVE; ERGOCALCIFEROL; NAPHTHALENE DERIVATIVE; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PARICALCITOL; PHOSPHORUS; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D;

ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HUMAN; METABOLISM; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CALCIUM; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TERIPARATIDE; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D;

EID: 26044437237     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. a edición (BM Brenner, ed). WB Saunders Company, p. 2103-2186, 2000.
2. Bover J, Rodríguez M, Trinidad P, Jara A, Martínez ME, Machado L, Llach F, Felsenfeld AJ.: Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney International 45: 953-961, 1994.
3. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (4 Supl. 3): S1-201, 2003.
4. Pahl M, Jara A, Bover J, Felsenfeld AJ.: Studies in a hemodialysis patient indicating that calcitriol may have a direct suppressive effect on bone. Nephron 71 (2): 218-223, 1995.
5. Slatopolsky E, Finch J, Brown A.: New vitamin D analogs. Kidney Int 63 (s85): 83, 2003.
6. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E.: A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30 (1): 105-112, 1997.
7. Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M, Wein Y, Webster J.: Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 63 (6): 2020-2027, 2003.
8. Hirata M, Katsumata K, Endo K, Fukushima N, Ohkawa H, Fukagawa M.: En subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 18 (9): 1770-6, 2003.
9. Goldsmith D, Ritz E, Covic A.: Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 66 (4): 1315-1333, 2004.
10. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernández E.: Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int (Supl. 85): S111-114, 2003.
11. Shoji T, Nishizawa Y.: Vitamin D and survival of hemodialysis patients. Clin Calcium 14 (9): 64-68, 2004.
12. Yonemura K, Fujimoto T, Fujigaki Y, Hishida A.: Vitamin D deficiency is implicated in reduced serum albumin concentrations in patients with end-stage renal disease. Am J Kidney Dis 36 (2): 337-344, 2000.
13. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R.: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 (5): 446-456, 2003.
14. Cardus A, Gallego C, Muray S, Marco MP, Parisi E, Aldea M, Fernández E.: Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells. Nefrologia (Supl. 2): 117-121, 2003.
15. Slatopolsky E, Cozzolino M, Finch JL.: Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 62 (4): 1277-1284, 2002.
16. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D.: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63 (4): 1483-1490, 2003.
17. Llach F, Yudd M.: Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38 (5 Supl. 5): S45-S50, 2001.
18. Martín KJ, González E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F.: Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38 (5 Supl. 5): S57-S63, 2001.
19. Ureña P, Frazão J.: Calcimimetic agents: Review and perspectives. Kidney Int 63 (s85): 91, 2003.
20. Rodríguez M, Nemeth E, Martín D.: The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 288 (2): F253-64, 2005.
21. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martín KJ.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium · phosphorus in secondary hyperparathyroidism. Kidney Int 63 (1): 248-254, 2003.
22. Block GA, Martín KJ, De Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 (15): 1516-1525, 2004.
23. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA.: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14 (3): 575-583, 2003.
24. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J. Daily intermittent decreases in serum levels of parathyroidhormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26 (2): 175-182, 2000.
25. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martín D.: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67 (2): 467-476, 2005.
26. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Barón R, Delling G, Demay MB.: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139 (10): 4391-4396, 1998.
27. Ogata H, Ritz E, Odoni G, Amann K, Orth SR.: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14 (4): 959-967, 2003.
28. Ureña P. Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 19 (Supl. 5): V27-33, 2004.
29. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, Mc-Cary LC, Olson KA, Turner SA, Martin KJ.: Achieving NKFK/ DOQI Trade mark bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 (2): 760-71, 2005.
30. Fraser WD, Ahmad AM, Vora JP.: The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis. Curr Opin Nephrol Hypertens 13 (4): 437-44, 2004.
31. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, Slatopolsky E.: Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 270 (3 Pt 2): F454-460, 1996.
32. Garfia B, Canadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almadén Y, Aguilera-Tejero E, Rodríguez M.: Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 13 (12): 2945-2952, 2002.
33. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM, Bourdeau JE.: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18 (2): 217-224, 1991.
34. Fernández E, Borras M, Pais B, Montoliu J.: Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol 6 (1): 132-135, 1995.
35. Al-Hejaili F, Kortas C, Leitch R, Heidenheim AP, Clement L, Nesrallah G, Lindsay RM. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 14 (9): 2322-8, 2003.
36. Cannata-Andía JB, Gómez Alonso C.: Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 17 (11): 1875-1878, 2002.
37. Lowrie EG, Lew NL.: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 (5): 458-482, 1990.
38. Brancaccio D, Tetta C, Gallieni M, Panichi V.: Inflammation, CRP, calcium overload and a high calcium-phosphate product: a «liaison dangereuse». Nephrol Dial Transplant 17 (2): 201-203, 2002.
39. Jara A, Felsenfeld AJ, Bover J, Kleeman CR. Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. Kidney Int 58 (3): 1023-1032, 2000.
40. Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, Akiba T, Port FK, Young EW.: Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (4): 661-71, 2004.
41. Torregrosa J, Moreno A, Mas M, Ybarra J, Fuster D.: Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodiálisis. Kidney Int 63 (s85): S88, 2003.
42. Price PA, Faus SA, Williamson MK.: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21 (5): 817-824, 2001.
43. Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H.: Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8 (3): 241-7, 2004.
44. Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, Surendran K.: Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol 24 (1): 25-38; 2004.
45. Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA.: Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens 13 (4): 417-422, 2004.
46. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide [human parathyroid hormone (1-34)] inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 278 (50): 50195-50202, 2003.